Details
| Stereochemistry | MIXED |
| Molecular Formula | C21H38O4 |
| Molecular Weight | 354.524 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 4 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCCO
InChI
InChIKey=SPOAFZKFCYREMW-FWYLUGOYSA-N
InChI=1S/C21H38O4/c1-3-4-13-21(2,25)14-10-12-18-17(19(23)16-20(18)24)11-8-6-5-7-9-15-22/h10,12,17-18,20,22,24-25H,3-9,11,13-16H2,1-2H3/b12-10+/t17-,18-,20-,21?/m1/s1
| Molecular Formula | C21H38O4 |
| Molecular Weight | 354.524 |
| Charge | 0 |
| Count |
|
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 4 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Rioprostil is a methylprostaglandin E1 analog. Rioprostil inhibits gastric acid secretion and enhances the gastric mucus-bicarbonate barrier. In peptic ulcer cases, it facilitates the healing process and the elimination of pain. Rioprostil can also be used to prevent recurrence of duodenal ulcers. However, its development has been discontinued in 2000.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:47:08 GMT 2025
by
admin
on
Mon Mar 31 18:47:08 GMT 2025
|
| Record UNII |
7JL402PVQR
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C78568
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7JL402PVQR
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
S-95
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
3529
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
77287-05-9
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
CHEMBL3301679
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
5299
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
D016630
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
100000080588
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
DTXSID701021622
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
SUB10327MIG
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
5311413
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
C90930
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
m9629
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
Assumed similar activity as prostaglandin E1
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
